TY - JOUR AU - Garattini, S. AU - Jakobsen, J. C. AU - Wetterslev, J. AU - Bertele, V. AU - Banzi, R. AU - Rath, A. PY - 2016 DA - 2016// TI - Evidence-based clinical practice: overview of threats to the validity of evidence and how to minimise them JO - Eur J Intern Med VL - 32 UR - https://doi.org/10.1016/j.ejim.2016.03.020 DO - 10.1016/j.ejim.2016.03.020 ID - Garattini2016 ER - TY - STD TI - Regulation (EC) No 141/2000 of The European Parliament and of The Council of 16 December 1999 on orphan medicinal products. 2000. [cited 2017 November 14]; Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF. UR - http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF ID - ref2 ER - TY - JOUR AU - Song, P. AU - Gao, J. AU - Inagaki, Y. AU - Kokudo, N. AU - Tang, W. PY - 2012 DA - 2012// TI - Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives JO - Intractable Rare Dis Res VL - 1 ID - Song2012 ER - TY - STD TI - National Institute of Health. Public Law 107–280 107th Congress. Rare Diseases Act. 2002. [cited 2017 November 14]; Available from: https://history.nih.gov/research/downloads/PL107-280.pdf. UR - https://history.nih.gov/research/downloads/PL107-280.pdf ID - ref4 ER - TY - STD TI - Rath AM, Nguengang Wakap S. Orphanet Report Series - Prevalence of rare diseases: Bibliographic data, Number 1. 2017. [cited 2017 November 14]; Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. UR - http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf ID - ref5 ER - TY - STD TI - Orphanet. 2017 [cited 2017 November 14]; Available from: http://www.orpha.net/consor/cgi-bin/index.php. UR - http://www.orpha.net/consor/cgi-bin/index.php ID - ref6 ER - TY - JOUR AU - Schlander, M. AU - Garattini, S. AU - Holm, S. AU - Kolominsky-Rabas, P. AU - Nord, E. AU - Persson, U. PY - 2014 DA - 2014// TI - Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders JO - J Comp Effectiveness Res VL - 3 UR - https://doi.org/10.2217/cer.14.34 DO - 10.2217/cer.14.34 ID - Schlander2014 ER - TY - JOUR AU - Bell, S. A. AU - Tudur Smith, C. PY - 2014 DA - 2014// TI - A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov JO - Orphanet J Rare Dis VL - 9 UR - https://doi.org/10.1186/s13023-014-0170-0 DO - 10.1186/s13023-014-0170-0 ID - Bell2014 ER - TY - STD TI - European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. 2009. [cited 2017 November 14]; Available from:  http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. UR - http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF ID - ref9 ER - TY - STD TI - Aymé S, Rodwell C. European Committee Expert Group on Rare Diseases. Report on the State of the Art of Rare Disease Activities in Europe. 2014. [cited 2017 November 14]; Available from: http://www.eucerd.eu/?page_id=15. UR - http://www.eucerd.eu/?page_id=15 ID - ref10 ER - TY - STD TI - Commission Of The European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of Regions on Rare Diseases: Europe’s challenge 2008. [cited 2017 November 14]; Available from: http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf. UR - http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf ID - ref11 ER - TY - STD TI - European Commission. Implementation Report on the Commission Communication on Rare Diseases: Europe’s challenges and council recommendation of 8 June 2009 on an action in the field of rare diseases. 2009. [cited 2017 November 14); Available from: https://ec.europa.eu/health//sites/health/files/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf. UR - https://ec.europa.eu/health//sites/health/files/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf ID - ref12 ER - TY - STD TI - U.S. Department of Health and Human Services. Federal Regulations. Title 21: Food and Drugs. PART 316—ORPHAN DRUGS. 2015. [cited 2017 November 14]; Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=316&showFR=1. UR - https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=316&showFR=1 ID - ref13 ER - TY - STD TI - International Rare Diseases Research Consortium. About. 2016. [cited 2017 November 14]; Available from: http://www.irdirc.org/. UR - http://www.irdirc.org/ ID - ref14 ER - TY - STD TI - Rath AM, Salamon V. Orphanet Report Series - Lists of medicinal products for rare diseases in Europe. 2017. [cited 2017 November 14]; Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf. UR - http://www.orpha.net/orphacom/cahiers/docs/GB/list_of_orphan_drugs_in_europe.pdf ID - ref15 ER - TY - STD TI - Food and Drug Administration. Rare Disease and Orphan Drug Designated Approvals. 2016. [cited 2017 November 14]; Available from: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373419.htm. UR - http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/drugandbiologicapprovalreports/ndaandblaapprovalreports/ucm373419.htm ID - ref16 ER - TY - JOUR AU - Joppi, R. AU - Bertele, V. AU - Garattini, S. PY - 2013 DA - 2013// TI - Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU JO - Eur J Clin Pharmacol VL - 69 UR - https://doi.org/10.1007/s00228-012-1423-2 DO - 10.1007/s00228-012-1423-2 ID - Joppi2013 ER - TY - STD TI - Westermark K, Holm BB, Soderholm M, Llinares-Garcia J, Riviere F, Aarum S, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nat Rev Drug Discov. 2011;10(5):341–9. Epub 3 May 2011. ID - ref18 ER - TY - STD TI - Food and Drug Administration. Novel Drugs Summary. 2015. [cited 2017 November 14]; Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm. UR - http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm474696.htm ID - ref19 ER - TY - STD TI - European Medicines Agency. Latest news. 2016. [cited 2017 November 14]; Available from: http://www.ema.europa.eu/. UR - http://www.ema.europa.eu/ ID - ref20 ER - TY - JOUR AU - Davis, C. AU - Lexchin, J. AU - Jefferson, T. AU - Gotzsche, P. AU - McKee, M. PY - 2016 DA - 2016// TI - ‘Adaptive pathways’ to drug authorisation: adapting to industry? JO - BMJ VL - 354 UR - https://doi.org/10.1136/bmj.i4437 DO - 10.1136/bmj.i4437 ID - Davis2016 ER - TY - STD TI - Health Action International, The International Society of Drug Bulletins, The Medicines in Europe Forum, The Mario Negri Institute for Pharmacological Research, Centre TNC. Joint Briefing Paper. ‘Adaptive licensing’ or ‘adaptive pathways’: Deregulation under the guise of earlier access. Brussels. 2015. [cited 2017 November 14]; Available from: http://www.isdbweb.org/en/publications/view/adaptive-licensing-or-adaptive-pathways-deregulation-under-the-guise-of-earlier-access. UR - http://www.isdbweb.org/en/publications/view/adaptive-licensing-or-adaptive-pathways-deregulation-under-the-guise-of-earlier-access ID - ref22 ER - TY - JOUR AU - Eichler, H. G. AU - Oye, K. AU - Baird, L. G. AU - Abadie, E. AU - Brown, J. AU - Drum, C. L. PY - 2012 DA - 2012// TI - Adaptive licensing: taking the next step in the evolution of drug approval JO - Clin Pharmacol Ther VL - 91 UR - https://doi.org/10.1038/clpt.2011.345 DO - 10.1038/clpt.2011.345 ID - Eichler2012 ER - TY - JOUR AU - Demotes-Mainard, J. AU - Kubiak, C. PY - 2011 DA - 2011// TI - A European perspective—the European clinical research infrastructures network JO - Ann Oncol VL - 22 UR - https://doi.org/10.1093/annonc/mdr425 DO - 10.1093/annonc/mdr425 ID - Demotes-Mainard2011 ER - TY - JOUR AU - Djurisic, S. AU - Rath, A. AU - Gaber, S. AU - Garattini, S. AU - Bertele, V. AU - Ngwabyt, S. N. PY - 2017 DA - 2017// TI - Barriers to the conduct of randomised clinical trials within all disease areas JO - Trials VL - 18 UR - https://doi.org/10.1186/s13063-017-2099-9 DO - 10.1186/s13063-017-2099-9 ID - Djurisic2017 ER - TY - STD TI - Laville M, Segrestin B, Masson Y, Ruano-Rodríguez C, Serra-Majem L, Hyesmaye M, et al. Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with? Trials. 2017;18(1):425. ID - ref26 ER - TY - STD TI - Neugebauer EAM, Rath A, Antoine S-L, Eikermann M, Seidel D, Koenen C, et al. Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 2017;18(1):427. ID - ref27 ER - TY - JOUR AU - Valdez, R. AU - Ouyang, L. AU - Bolen, J. PY - 2016 DA - 2016// TI - Public health and rare diseases: oxymoron no more JO - Prev Chronic Dis VL - 13 ID - Valdez2016 ER - TY - JOUR AU - Shash, E. AU - Negrouk, A. AU - Marreaud, S. AU - Golfinopoulos, V. AU - Lacombe, D. AU - Meunier, F. PY - 2013 DA - 2013// TI - International clinical trials setting for rare cancers: organisational and regulatory constraints-the EORTC perspective JO - Ecancermedicalscience VL - 7 UR - https://doi.org/10.3332/ecancer.2013.321 DO - 10.3332/ecancer.2013.321 ID - Shash2013 ER - TY - JOUR AU - Boycott, K. M. AU - Vanstone, M. R. AU - Bulman, D. E. AU - MacKenzie, A. E. PY - 2013 DA - 2013// TI - Rare-disease genetics in the era of next-generation sequencing: discovery to translation JO - Nat Rev Genet VL - 14 UR - https://doi.org/10.1038/nrg3555 DO - 10.1038/nrg3555 ID - Boycott2013 ER - TY - STD TI - Orphanet. Orphadata. 2016. [cited 2017 November 14]; Available from: http://www.orphadata.org/cgi-bin/inc/product1.inc.php. UR - http://www.orphadata.org/cgi-bin/inc/product1.inc.php ID - ref31 ER - TY - STD TI - Rath AM, Peixoto S. Disease registries in Europe. 2016. [cited 2017 November 14]; Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf. UR - http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf ID - ref32 ER - TY - JOUR AU - Augustine, E. F. AU - Adams, H. R. AU - Mink, J. W. PY - 2013 DA - 2013// TI - Clinical trials in rare disease: challenges and opportunities JO - J Child Neurol VL - 28 UR - https://doi.org/10.1177/0883073813495959 DO - 10.1177/0883073813495959 ID - Augustine2013 ER - TY - JOUR AU - Rath, A. AU - Olry, A. AU - Dhombres, F. AU - Brandt, M. M. AU - Urbero, B. AU - Ayme, S. PY - 2012 DA - 2012// TI - Representation of rare diseases in health information systems: the Orphanet approach to serve a wide range of end users JO - Hum Mutat VL - 33 UR - https://doi.org/10.1002/humu.22078 DO - 10.1002/humu.22078 ID - Rath2012 ER - TY - STD TI - Commission Expert Group for Rare Diseases. Recommendation on ways to improve codification for rare diseases. 2014. [cited 2017 November 14]; Available from: https://ec.europa.eu/health//sites/health/files/rare_diseases/docs/recommendation_coding_cegrd_en.pdf. UR - https://ec.europa.eu/health//sites/health/files/rare_diseases/docs/recommendation_coding_cegrd_en.pdf ID - ref35 ER - TY - STD TI - European Union Committee of Experts on Rare Diseases. EUCERD core recommendations on rare disease patient registration and data collection to the European Commission, Member States and all stakeholders. 2013. [cited 2017 November 14]; Available from: http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf. UR - http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf ID - ref36 ER - TY - STD TI - International Rare Diseases Research Consortium. Policies and guidelines. 2013. [cited 2017 November 14); Available from: http://www.irdirc.org/wp-content/uploads/2013/06/IRDiRC_policies_24MayApr2013.pdf. UR - http://www.irdirc.org/wp-content/uploads/2013/06/IRDiRC_policies_24MayApr2013.pdf ID - ref37 ER - TY - STD TI - Rodger S, Lochmuller H, Tassoni A, Gramsch K, Konig K, Bushby K, et al. The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis. 2013;8:171. Epub 24 Oct 2013. ID - ref38 ER - TY - JOUR AU - Potter, B. K. AU - Khangura, S. D. AU - Tingley, K. AU - Chakraborty, P. AU - Little, J. PY - 2016 DA - 2016// TI - Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? JO - Genet Med VL - 18 UR - https://doi.org/10.1038/gim.2015.42 DO - 10.1038/gim.2015.42 ID - Potter2016 ER - TY - JOUR AU - Tudur Smith, C. AU - Williamson, P. R. AU - Beresford, M. W. PY - 2014 DA - 2014// TI - Methodology of clinical trials for rare diseases JO - Best Pract Res Clin Rheumatol VL - 28 UR - https://doi.org/10.1016/j.berh.2014.03.004 DO - 10.1016/j.berh.2014.03.004 ID - Tudur Smith2014 ER - TY - JOUR AU - Gupta, S. AU - Faughnan, M. E. AU - Tomlinson, G. A. AU - Bayoumi, A. M. PY - 2011 DA - 2011// TI - A framework for applying unfamiliar trial designs in studies of rare diseases JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2010.12.019 DO - 10.1016/j.jclinepi.2010.12.019 ID - Gupta2011 ER - TY - JOUR AU - Korn, E. L. AU - McShane, L. M. AU - Freidlin, B. PY - 2013 DA - 2013// TI - Statistical challenges in the evaluation of treatments for small patient populations JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3004018 DO - 10.1126/scitranslmed.3004018 ID - Korn2013 ER - TY - JOUR AU - Cornu, C. AU - Kassai, B. AU - Fisch, R. AU - Chiron, C. AU - Alberti, C. AU - Guerrini, R. PY - 2013 DA - 2013// TI - Experimental designs for small randomised clinical trials: an algorithm for choice JO - Orphanet J Rare Dis VL - 8 UR - https://doi.org/10.1186/1750-1172-8-48 DO - 10.1186/1750-1172-8-48 ID - Cornu2013 ER - TY - JOUR AU - Gagne, J. J. AU - Thompson, L. AU - O’Keefe, K. AU - Kesselheim, A. S. PY - 2014 DA - 2014// TI - Innovative research methods for studying treatments for rare diseases: methodological review JO - BMJ VL - 349 UR - https://doi.org/10.1136/bmj.g6802 DO - 10.1136/bmj.g6802 ID - Gagne2014 ER - TY - JOUR AU - Button, K. S. AU - Ioannidis, J. P. AU - Mokrysz, C. AU - Nosek, B. A. AU - Flint, J. AU - Robinson, E. S. PY - 2013 DA - 2013// TI - Power failure: why small sample size undermines the reliability of neuroscience JO - Nat Rev Neurosci VL - 14 UR - https://doi.org/10.1038/nrn3475 DO - 10.1038/nrn3475 ID - Button2013 ER - TY - JOUR AU - Parmar, M. K. AU - Sydes, M. R. AU - Morris, T. P. PY - 2016 DA - 2016// TI - How do you design randomised trials for smaller populations? A framework JO - BMC Med VL - 14 UR - https://doi.org/10.1186/s12916-016-0722-3 DO - 10.1186/s12916-016-0722-3 ID - Parmar2016 ER - TY - JOUR AU - Hilgers, R. D. AU - Roes, K. AU - Stallard, N. PY - 2016 DA - 2016// TI - Directions for new developments on statistical design and analysis of small population group trials JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0464-5 DO - 10.1186/s13023-016-0464-5 ID - Hilgers2016 ER - TY - JOUR AU - Roes, K. C. PY - 2016 DA - 2016// TI - A framework: make it useful to guide and improve practice of clinical trial design in smaller populations JO - BMC Med VL - 14 UR - https://doi.org/10.1186/s12916-016-0752-x DO - 10.1186/s12916-016-0752-x ID - Roes2016 ER - TY - STD TI - Nikolakopoulos S, Roes KC, van der Tweel I. Sequential designs with small samples: evaluation and recommendations for normal responses. Stat Methods Med Res. 2016. Epub 28 Jun 2016. ID - ref49 ER - TY - JOUR AU - Ioannidis, J. P. AU - Hozo, I. AU - Djulbegovic, B. PY - 2013 DA - 2013// TI - Optimal type I and type II error pairs when the available sample size is fixed JO - J Clin Epidemiol VL - 66 UR - https://doi.org/10.1016/j.jclinepi.2013.03.002 DO - 10.1016/j.jclinepi.2013.03.002 ID - Ioannidis2013 ER - TY - JOUR AU - Vickers, A. J. AU - Scardino, P. T. PY - 2009 DA - 2009// TI - The clinically-integrated randomized trial: proposed novel method for conducting large trials at low cost JO - Trials VL - 10 UR - https://doi.org/10.1186/1745-6215-10-14 DO - 10.1186/1745-6215-10-14 ID - Vickers2009 ER - TY - STD TI - European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. [cited 2017 November 14); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003616.pdf ID - ref52 ER - TY - JOUR AU - Mauer, M. AU - Collette, L. AU - Bogaerts, J. PY - 2012 DA - 2012// TI - Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size JO - Eur J Cancer VL - 48 UR - https://doi.org/10.1016/j.ejca.2011.12.024 DO - 10.1016/j.ejca.2011.12.024 ID - Mauer2012 ER - TY - JOUR AU - Tamura, R. N. AU - Krischer, J. P. AU - Pagnoux, C. AU - Micheletti, R. AU - Grayson, P. C. AU - Chen, Y. F. PY - 2016 DA - 2016// TI - A small n sequential multiple assignment randomized trial design for use in rare disease research JO - Contemp Clin Trials VL - 46 UR - https://doi.org/10.1016/j.cct.2015.11.010 DO - 10.1016/j.cct.2015.11.010 ID - Tamura2016 ER - TY - JOUR AU - Hlavin, G. AU - Koenig, F. AU - Male, C. AU - Posch, M. AU - Bauer, P. PY - 2016 DA - 2016// TI - Evidence, eminence and extrapolation JO - Stat Med VL - 35 UR - https://doi.org/10.1002/sim.6865 DO - 10.1002/sim.6865 ID - Hlavin2016 ER - TY - STD TI - Guideline on clinical trials in small populations. Doc. Ref. CHMP/EWP/83561/2005, 2006. [cited 2017 November 14); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf. UR - http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf ID - ref56 ER - TY - JOUR AU - Billingham, L. AU - Malottki, K. AU - Steven, N. PY - 2016 DA - 2016// TI - Research methods to change clinical practice for patients with rare cancers JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00396-4 DO - 10.1016/S1470-2045(15)00396-4 ID - Billingham2016 ER - TY - STD TI - Rheinisch-Westfälische Technische Hochschule Aachen University. Integrated DEsign and AnaLysis of small population group trials (IDEAL). 2013. [cited 2017 November 14); Available from: http://www.rwth-aachen.de/go/id/ehgl/?lidx=1. UR - http://www.rwth-aachen.de/go/id/ehgl/?lidx=1 ID - ref58 ER - TY - STD TI - Warwick Medical School. Innovative methodology for small populations research (INSPIRE). 2016. [cited 2017 November 14); Available from: https://www2.warwick.ac.uk/fac/med/research/hscience/stats/currentprojects/inspire/. UR - https://www2.warwick.ac.uk/fac/med/research/hscience/stats/currentprojects/inspire/ ID - ref59 ER - TY - STD TI - Community Research and Development Information Service. Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (ASTERIX). 2016. [cited 2017 November 14); Available from: http://cordis.europa.eu/projects/rcn/110076_en.html. UR - http://cordis.europa.eu/projects/rcn/110076_en.html ID - ref60 ER - TY - STD TI - International Rare Diseases Research Consortium. International Rare Diseases Research Consortium’s Task Force on Small Population Clinical Trials. 2016. [cited 2017 November 14); Available from: http://www.irdirc.org/activities/current-activities/tf-spct/. UR - http://www.irdirc.org/activities/current-activities/tf-spct/ ID - ref61 ER - TY - JOUR AU - Joppi, R. AU - Bertele, V. AU - Garattini, S. PY - 2009 DA - 2009// TI - Orphan drug development is not taking off JO - Br J Clin Pharmacol VL - 67 UR - https://doi.org/10.1111/j.1365-2125.2009.03369.x DO - 10.1111/j.1365-2125.2009.03369.x ID - Joppi2009 ER - TY - STD TI - Heads of Medicines Agencies. Clinical trials facilitation group. 2016. [cited 2017 November 14); Available from: http://www.hma.eu/ctfg.html. UR - http://www.hma.eu/ctfg.html ID - ref63 ER - TY - STD TI - Heads of Medicines Agencies. Metrics on participation of National Competent Authorities. 2016. [cited 2017 November 14); Available from: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2016_05_CTFG_Metrics_on_NCA_participation_Jan15_Jan16.pdf. UR - http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2016_05_CTFG_Metrics_on_NCA_participation_Jan15_Jan16.pdf ID - ref64 ER - TY - STD TI - European Medicines Agency. Updates. 2017. [cited 2017 November 14]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mid=WC0b01ac05808768df. UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mid=WC0b01ac05808768df ID - ref65 ER - TY - JOUR AU - Gluud, C. AU - Brok, J. AU - Gong, Y. AU - Koretz, R. L. PY - 2007 DA - 2007// TI - Hepatology may have problems with putative surrogate outcome measures JO - J Hepatol VL - 46 UR - https://doi.org/10.1016/j.jhep.2007.01.003 DO - 10.1016/j.jhep.2007.01.003 ID - Gluud2007 ER - TY - JOUR AU - Molenberghs, G. AU - Geys, H. AU - Buyse, M. PY - 2001 DA - 2001// TI - Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes JO - Stat Med VL - 20 UR - https://doi.org/10.1002/sim.923 DO - 10.1002/sim.923 ID - Molenberghs2001 ER - TY - JOUR AU - Molenberghs, G. AU - Burzykowski, T. AU - Alonso, A. AU - Assam, P. AU - Tilahun, A. AU - Buyse, M. PY - 2010 DA - 2010// TI - A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials JO - Stat Methods Med Res VL - 19 UR - https://doi.org/10.1177/0962280209105015 DO - 10.1177/0962280209105015 ID - Molenberghs2010 ER - TY - STD TI - Ensor H, Lee RJ, Sudlow C, Weir CJ. Statistical approaches for evaluating surrogate outcomes in clinical trials: a systematic review. J Biopharm Stat. 2015:1–21. Epub 24 Sep 2015. ID - ref69 ER - TY - JOUR AU - Joppi, R. AU - Gerardi, C. AU - Bertele, V. AU - Garattini, S. PY - 2016 DA - 2016// TI - Letting post-marketing bridge the evidence gap: the case of orphan drugs JO - BMJ VL - 353 UR - https://doi.org/10.1136/bmj.i2978 DO - 10.1136/bmj.i2978 ID - Joppi2016 ER - TY - STD TI - International Rare Diseases Research Consortium. Patient-centered outcome measures initiatives in the field of rare diseases. 2016. [cited 2017 November 14]; Available from: http://www.irdirc.org/wp-content/uploads/2016/03/PCOM_Post-Workshop_Report_Final.pdf. UR - http://www.irdirc.org/wp-content/uploads/2016/03/PCOM_Post-Workshop_Report_Final.pdf ID - ref71 ER - TY - JOUR AU - Jakobsen, J. C. AU - Gluud, C. AU - Winkel, P. AU - Lange, T. AU - Wetterslev, J. PY - 2014 DA - 2014// TI - The thresholds for statistical and clinical significance—a five-step procedure for evaluation of intervention effects in randomised clinical trials JO - BMC Med Res Methodol VL - 14 UR - https://doi.org/10.1186/1471-2288-14-34 DO - 10.1186/1471-2288-14-34 ID - Jakobsen2014 ER - TY - JOUR AU - Perea-Milla, E. AU - Aycaguer, L. C. AU - Cerda, J. C. AU - Saiz, F. G. AU - Rivas-Ruiz, F. AU - Danet, A. PY - 2009 DA - 2009// TI - Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index JO - Trials VL - 10 UR - https://doi.org/10.1186/1745-6215-10-70 DO - 10.1186/1745-6215-10-70 ID - Perea-Milla2009 ER - TY - JOUR AU - Putzeist, M. AU - Mantel-Teeuwisse, A. K. AU - Wied, C. C. AU - Hoes, A. W. AU - Leufkens, H. G. AU - Vrueh, R. L. PY - 2013 DA - 2013// TI - Drug development for exceptionally rare metabolic diseases: challenging but not impossible JO - Orphanet J Rare Dis VL - 8 UR - https://doi.org/10.1186/1750-1172-8-179 DO - 10.1186/1750-1172-8-179 ID - Putzeist2013 ER - TY - STD TI - Core Outcome Measures in Effectiveness Trials Initiative. Core Outcome Measures in Effectiveness Trials (COMET). 2016. [cited 2017 November 14]; Available from: http://www.comet-initiative.org. UR - http://www.comet-initiative.org ID - ref75 ER - TY - STD TI - International Society for Pharmacoeconomics and Outcomes Research. About. 2017. [cited 2017 November 14]; Available from: http://www.ispor.org. UR - http://www.ispor.org ID - ref76 ER - TY - STD TI - International Society for Pharmacoeconomics and Outcomes Research. Clinical Outcome Assessment (COA) in Rare Disease Clinical Trials—Emerging Good Practices: Report of the ISPOR Rare Disease Trials COA Measurement Task Force. 2016. [cited 2017 November 14]; Available from: http://www.ispor.org/TaskForces/ClinicalOutcomesAssessment-RareDisease-ClinicalTrials.asp. UR - http://www.ispor.org/TaskForces/ClinicalOutcomesAssessment-RareDisease-ClinicalTrials.asp ID - ref77 ER - TY - JOUR AU - Matza, L. S. AU - Patrick, D. L. AU - Riley, A. W. AU - Alexander, J. J. AU - Rajmil, L. AU - Pleil, A. M. PY - 2013 DA - 2013// TI - Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force JO - Value Health VL - 16 UR - https://doi.org/10.1016/j.jval.2013.04.004 DO - 10.1016/j.jval.2013.04.004 ID - Matza2013 ER - TY - STD TI - LEUKOTREAT. Therapeutic strategies for leukodystrophy affected patients. LeukoDataBase & Ethics. 2015. [cited 2017 November 14]; Available from: http://www.leukotreat.eu/leukodatabase-ethics.php. UR - http://www.leukotreat.eu/leukodatabase-ethics.php ID - ref79 ER - TY - STD TI - Tafuri G, Pagnini M, Moseley J, Massari M, Petavy F, Behring A, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82(4):965–73. Epub 2 Jun 2016. ID - ref80 ER - TY - STD TI - European Union Committee of Experts on Rare Diseases. Recommendation to the European Commission and Member States on improving informed decisions based on the clinical added value of orphan medicinal products information flow. 2012. [cited 2017 November 14]; Available from: http://www.eucerd.eu/?post_type=document&p=1446. UR - http://www.eucerd.eu/?post_type=document&p=1446 ID - ref81 ER - TY - JOUR AU - Forman, J. AU - Taruscio, D. AU - Llera, V. A. AU - Barrera, L. A. AU - Cote, T. R. AU - Edfjall, C. PY - 2012 DA - 2012// TI - The need for worldwide policy and action plans for rare diseases JO - Acta Paediatr VL - 101 UR - https://doi.org/10.1111/j.1651-2227.2012.02705.x DO - 10.1111/j.1651-2227.2012.02705.x ID - Forman2012 ER - TY - STD TI - Skoog M, Saarimäki JM, Gluud C, Sheinin M, Erlendsson K, Aamdal S. Transparency and registration in clinical research in the Nordic countries (Report). Nordic Trial Alliance, NordForsk. Oslo. Norge. 2015:1–108. (cited 2017 November 14]; Available from: http://nta.nordforsk.org/projects/nta_transparency_report.pdf. UR - http://nta.nordforsk.org/projects/nta_transparency_report.pdf ID - ref83 ER - TY - JOUR AU - Bajard, A. AU - Chabaud, S. AU - Cornu, C. AU - Castellan, A. C. AU - Malik, S. AU - Kurbatova, P. PY - 2016 DA - 2016// TI - An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials JO - J Clin Epidemiol VL - 69 UR - https://doi.org/10.1016/j.jclinepi.2015.06.024 DO - 10.1016/j.jclinepi.2015.06.024 ID - Bajard2016 ER - TY - STD TI - Bolignano D, Pisano A. Good-quality research in rare diseases: trials and tribulations. Pediatr Nephrol. 2016;31:217-23. Epub 29 Jan 2016. ID - ref85 ER - TY - STD TI - Patient-Centered Outcome Measures Research Institute. About. 2017. [cited 2017 November 14]; Available from: http://www.pcori.org/about-us. UR - http://www.pcori.org/about-us ID - ref86 ER - TY - JOUR AU - Ahmed, R. AU - Duerr, U. AU - Gavenis, K. AU - Hilgers, R. AU - Gross, O. PY - 2014 DA - 2014// TI - Challenges for academic investigator-initiated pediatric trials for rare diseases JO - Clin Ther VL - 36 UR - https://doi.org/10.1016/j.clinthera.2014.01.013 DO - 10.1016/j.clinthera.2014.01.013 ID - Ahmed2014 ER - TY - STD TI - Friede T, Rover C, Wandel S, Neuenschwander B. Meta-analysis of few small studies in orphan diseases. Res Synth Methods. 2016;8:79-91. Epub 30 Jun 2016. ID - ref88 ER - TY - JOUR AU - Wetterslev, J. AU - Thorlund, K. AU - Brok, J. AU - Gluud, C. PY - 2008 DA - 2008// TI - Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis JO - J Clin Epidemiol VL - 61 UR - https://doi.org/10.1016/j.jclinepi.2007.03.013 DO - 10.1016/j.jclinepi.2007.03.013 ID - Wetterslev2008 ER - TY - JOUR AU - Imberger, G. AU - Thorlund, K. AU - Gluud, C. AU - Wetterslev, J. PY - 2016 DA - 2016// TI - False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review JO - BMJ Open VL - 6 UR - https://doi.org/10.1136/bmjopen-2016-011890 DO - 10.1136/bmjopen-2016-011890 ID - Imberger2016 ER - TY - JOUR AU - Kulinskaya, E. AU - Wood, J. PY - 2014 DA - 2014// TI - Trial sequential methods for meta-analysis JO - Res Synth Methods VL - 5 UR - https://doi.org/10.1002/jrsm.1104 DO - 10.1002/jrsm.1104 ID - Kulinskaya2014 ER - TY - JOUR AU - Ioannidis, J. P. PY - 2014 DA - 2014// TI - How to make more published research true JO - PLoS Med VL - 11 UR - https://doi.org/10.1371/journal.pmed.1001747 DO - 10.1371/journal.pmed.1001747 ID - Ioannidis2014 ER - TY - JOUR AU - Alberts, B. AU - Kirschner, M. W. AU - Tilghman, S. AU - Varmus, H. PY - 2014 DA - 2014// TI - Rescuing US biomedical research from its systemic flaws JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1404402111 DO - 10.1073/pnas.1404402111 ID - Alberts2014 ER - TY - JOUR AU - Ioannidis, J. P. AU - Fanelli, D. AU - Dunne, D. D. AU - Goodman, S. N. PY - 2015 DA - 2015// TI - Meta-research: evaluation and improvement of research methods and practices JO - PLoS Biol VL - 13 UR - https://doi.org/10.1371/journal.pbio.1002264 DO - 10.1371/journal.pbio.1002264 ID - Ioannidis2015 ER - TY - JOUR AU - Gotzsche, P. C. PY - 1996 DA - 1996// TI - Blinding during data analysis and writing of manuscripts JO - Control Clin Trials VL - 17 UR - https://doi.org/10.1016/0197-2456(95)00263-4 DO - 10.1016/0197-2456(95)00263-4 ID - Gotzsche1996 ER - TY - JOUR AU - MacCoun, R. AU - Perlmutter, S. PY - 2015 DA - 2015// TI - Blind analysis: hide results to seek the truth JO - Nature VL - 526 UR - https://doi.org/10.1038/526187a DO - 10.1038/526187a ID - MacCoun2015 ER - TY - STD TI - The Academy of Medical Sciences Medical Research Council. Symposium Report. Reproducibility and reliability of biomedical research: improving research practice. Welcome Trust. 2015 [cited 2017 November 14]; Available from: http://www.acmedsci.ac.uk/policy/policy-projects/reproducibility-and-reliability-of-biomedical-research/. UR - http://www.acmedsci.ac.uk/policy/policy-projects/reproducibility-and-reliability-of-biomedical-research/ ID - ref97 ER - TY - JOUR AU - Jarvinen, T. L. AU - Sihvonen, R. AU - Bhandari, M. AU - Sprague, S. AU - Malmivaara, A. AU - Paavola, M. PY - 2014 DA - 2014// TI - Blinded interpretation of study results can feasibly and effectively diminish interpretation bias JO - J Clin Epidemiol VL - 67 UR - https://doi.org/10.1016/j.jclinepi.2013.11.011 DO - 10.1016/j.jclinepi.2013.11.011 ID - Jarvinen2014 ER -